These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 157801)

  • 21. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V; Van Oosterom A; Mouridsen HT; Cheix F; Somers R; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
    Kurzrock R; Yap BS; Plager C; Papdopoulos N; Benjamin RS; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1984 Aug; 7(4):305-7. PubMed ID: 6741860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
    Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
    Muggia FM; Tsiatis AA; O'Connell MJ; Glick JH; Opfell RW; Coren A
    Cancer Treat Rep; 1984 Mar; 68(3):551-3. PubMed ID: 6231103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
    Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC
    Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M; Chan TC; Cleary S; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of PALA.
    Gralla RJ; Casper ES; Natale RB; Yagoda A; Young CW
    Cancer Treat Rep; 1980; 64(12):1301-5. PubMed ID: 7471120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
    Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
    [No Abstract]   [Full Text] [Related]  

  • 36. PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
    Muss HB; Bundy B; DiSaia PJ; Stehman FB; Beecham J
    Am J Clin Oncol; 1984 Dec; 7(6):741-4. PubMed ID: 6528869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Muss HB; Slavik M; Bundy B; Stehman FB; Creasman WT
    Am J Clin Oncol; 1984 Jun; 7(3):257-60. PubMed ID: 6731346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Nichols WC; Ingle JN; Kvols LK
    Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
    Leung SW; Fung KP; Choy YM; Lee CY
    Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Presant CA; Ardalan B; Multhauf P; Chan C; Staples R; Green L; Browning S; Carr BI; Chang FF; Thayer W
    Med Pediatr Oncol; 1983; 11(3):162-3. PubMed ID: 6222250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.